Pembrolizumab was more superior to chemotherapy in patients with ≥10% PD-L1 combined positive score (prevalence: 30.3%): median OS, 8.6 vs. 4.2 months (HR: 0.57, p = 0.005); PD-L1 combined positive score was the % of PD-L1+ tumor and immune cells relative to tumor cells, Dako PD-L1 IHC 22C3 pharmDx assay. The gene discussed is CD274; the disease is neoplasm.